甲状旁腺激素(1-34)、多聚赖氨酸应用于口腔种植体表面促成骨作用研究

摘要
图/表
参考文献
相关文章 (11)

全文: PDF (1057 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的研究甲状旁腺激素(parathyroid hormone, PTH)(1-34)、多聚赖氨酸应用于种植体表面的促成骨作用。方法将PTH(1-34)和多聚赖氨酸通过层层自组装的方式涂层到种植体表面。按照涂层制备方法和PTH(1-34)浓度将种植体分为4个组: PLL载体组(A组)、10 μg组(B组)、100 μg组(C组)和空白对照组(D组)。使用ELISA法探索该涂层的体外药物释放规律;将小鼠胚胎成骨前体细胞MC3T3-E1接种于涂层后的种植体表面,使用MTT法、碱性磷酸酶半定量、PCR等方法,检测该涂层在体外条件下对成骨细胞生物学行为的影响。结果通过层层自组装技术于钛种植体表面制成的PLL-PTH(1-34)聚电解质多层膜涂层在初始阶段表现出明显的释放过程,随后释放程度趋于平缓,第14天时仍可检出PTH(1-34)。MTT检测:第5 天时C组OD值(1.738±0.026)与第1天(1.663±0.045)相比有明显升高(P=0.0219)。碱性磷酸酶半定量:第14天时,C组(3.377±0.336)U/gprot明显高于A组(2.537±0.083)U/gprot、B组(2.843±0.060)U/gprot和D组(2.063±0.061)U/gprot,差异均有统计学意义(P<0.05)。PCR检测:ALP基因于第7天时各组表达水平最高,且C组明显高于A、B、D三组,差异均有统计学意义(P<0.05);OCN基因于第14天时各组表达水平最高,且C组明显高于A、B、D三组,差异均有统计学意义(P<0.05)。结论在钛种植体表面可以通过层层自组装技术制成PLL-PTH(1-34)聚电解质多层膜涂层。通过该技术可以实现PTH(1-34)较长时间的局部释放,从而促进其表面成骨细胞的增殖和分化。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王星星
	罗小龙
	吴刚
	韩旭
	郭晓晶
	汪大林

关键词 ： PTH(1-34), 多聚赖氨酸, 层层自组装技术, 种植体

Abstract：Objective To promote osteogenesis, parathyroid hormone which can promote bone formation was used to process surface of implant material.Methods Parathyroid hormone PTH (1-34) and polylysine were coated to the surface of the implant material through layer by layer self-assemble technique. ELISA was used to explore the in vitro pharmacokinetics regularity of the coating. The mouse embryos osteogenesis precursor cells MC3T3 E1 were seeded on the coated implant material surface. MTT, alkaline phosphatase semi-quantitative and PCR Methods were used to detect the in vitro influence of osteoblast biology behavior.Results PLL - PTH (1-34) polyelectrolyte multilayer membrane coating made by layer by layer self-assemble technique showed significant release process in the initial phase, then the release leveled off, and PTH (1-34) could be detected until 14 d. MTT: OD value of group C (1.738±0.026) on the 5 d elevated compared with 1 d (1.663±0.045) (P=0.0219). Alkaline phosphatase semi-quantitative: activity of alkaline phosphatase in group C (3.377±0.336) U/gprot was higher than in group A (2.537±0.083) U/gprot, B (2.843±0.060) U/gprot and D(2.063±0.061) U/gprot; the difference was statistically significant (P<0.05). PCR: expression level of ALP in four groups were highest on 7 d, and in group C was higher than in groups A, B and D (the difference was statistically significant, P<0.05); expression level of OCN in four groups were highest on 14 d, and in group C was higher than in groups A, B and D (the difference was statistically significant, P<0.05).Conclusions PLL - PTH (1-34) polyelectrolyte multilayer membrane can be made on implant material surface through layer by layer self-assemble technique. PTH (1-34) can release for a long time (14 d) by this technique, so as to promote proliferation and differentiation of the osteoblasts seeded on the surface.

Key words： PTH(1-34) polylysine layer by layer self-assemble technique implant

收稿日期: 2016-03-20

ZTFLH:

R782

通讯作者: 汪大林,E-mail: Wang_Dento@163.com

作者简介: 王星星,硕士研究生。

引用本文:

王星星, 罗小龙, 吴刚, 韩旭, 郭晓晶, 汪大林. 甲状旁腺激素(1-34)、多聚赖氨酸应用于口腔种植体表面促成骨作用研究[J]. 武警医学, 2016, 27(8): 814-818. WANG Xingxing, LUO Xiaolong, WU Gang, HAN Xu, GUO Xiaojing, and WANG Dalin. A study on osteogenesis promoted by PTH (1-34) and polylysine coating on the surface of implant. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(8): 814-818.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2016/V27/I8/814

[1]	Branemark P I. Osseointegration and its experimental background [J]. J Prosthet Dent,1983,50(3):399-410.
[2]	Qin L, Raggatt L J, Partridge N C. Parathyroid hormone: a double-edged sword for bone metabolism [J]. Trends Endocrinol Metab, 2004,15(2):60-65.
[3]	Farra R, Sheppard N F, Mccabe L, et al. First-in-human testing of a wirelessly controlled drug delivery microchip [J]. Sci Transl Med,2012,4(122):122ra121.
[4]	Nardi A, Ventura L, Cozzi L, et al. The bone anabolic therapy [J]. Aging Clin Exp Res, 2013, 25 (Suppl 1):S121-S124.
[5]	Hadji P, Zanchetta J R, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures [J]. Osteoporos Int, 2012,23(8):2141-2150.
[6]	Mcneilly T, Mcnally C, Finch M, et al. Recombinant PTH: a study of the outcome of teriparatide therapy for 138 patients with osteoporosis [J]. Ulster Med J, 2013,82(2):89-93.
[7]	Gabet Y, Muller R, Levy J, et al. Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis [J]. Bone, 2006, 39(2): 276-282.
[8]	Shirota T, Tashiro M, Ohno K, et al. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats [J]. J Oral Maxillofac Surg, 2003, 61(4): 471-480.
[9]	Almagro M I, Roman-Blas J A, Bellido M, et al. Pth[1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis [J]. Clin Oral Implants Res, 2013, 24(9): 1027-1034.
[10]	Ohkawa Y, Tokunaga K, Endo N. Intermittent administration of human parathyroid hormone (1-34) increases new bone formation on the interface of hydroxyapatitecoated titanium rods implanted into ovariectomized rat femora [J]. J Orthop Sci, 2008,13(6):533-542.
[11]	Li Y F, Li X D, Bao C Y, et al. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface [J]. Osteoporos Int, 2013, 24(3): 1063-1071.
[12]	Onyia J E, Helvering L M, Gelbert L, et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (pth) in rat bone: an analysis by DNA microarray [J]. J Cell Biochem, 2005, 95(2): 403-418.
[13]	Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis [J]. J Biol Chem, 2007, 282(45): 33086-33097.
[14]	Jilka R L, O'brien C A, Ali A A, et al. Intermittent pth stimulates periosteal bone formation by actions on post-mitotic preosteoblasts [J]. Bone, 2009, 44(2): 275-286.
[15]	Augustine M, Horwitz M J. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis [J]. Curr Osteoporos Rep, 2013, 11(4): 400-406.
[16]	Tam C S, Heersche J N, Murray T M, et al. Parathyroid hormone stimulates the bone apposition rateindependently of its resorptive action: Differential effects of intermittent and continuous administration [J]. Endocrinology,1982,110(2):506-512.
[17]	Datta N S, Abou-Samra A B. Pth and pthrp signaling in osteoblasts [J]. Cell Signal,2009,21(8):1245-1254.
[18]	Ishizuya T. Effects of parathyroid hormone on bone metabolism : differences between intermittent and continuous treatment [J]. Clin Calcium, 2012, 22(3): 357-363.
[19]	Jilka R L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH [J]. Bone, 2007, 40(6): 1434-1446.
[20]	Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate [J]. N Engl J Med, 2005, 353(6): 566-575.
[21]	Hodsman A B, Bauer D C, Dempster D W, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use [J]. Endocr Rev, 2005, 26(5):688-703.
[22]	刘明,潘薇,陈德才.甲状旁腺激素治疗骨质疏松症的研究进展 [J]. 中华骨质疏松和骨矿盐疾病杂志, 2012,5(2):151-156.
[23]	Valderrama P, Jung R E, Thoma D S, et al. Evaluation of parathyroid hormone bound to a synthetic matrix for guided bone regeneration around dental implants: a histomorphometric study in dogs [J]. J Periodontol, 2010, 81(5): 737-747.
[24]	Yu X, Wang L, Jiang X, et al. Biomimetic cap coating incorporated with parathyroid hormone improves the osseointegration of titanium implant [J]. J Mater Sci Mater Med, 2012, 23(9): 2177-2186.